Clinical Trial: Lifemel Honey to Reduce Leucopenia During Chemotherapy

This study will include 60 patients with early breast cancer referred to receive adjuvant chemotherapy with AC ( adriamycin- cyclophosphamide) or CAF ( adriamycin- cyclophosphamide- 5- fluorouracil ) combinations. These patients will receive every day one spoon of Lifemel honey or regular honey ( double blind)- during the adjuvant chemotherapy .Every week a WBC count will be performed in order to record the influence of Lifemel on myelotoxicity.

MedlinePlus related topics:  Breast Cancer
Genetics Home Reference related topics:  breast cancer

Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study

Official Title: Lifemel Honey During Adjuvant Chemotherapy for Breast Cancer Patients to Prevent Leucopenia

Further study details as provided by Rambam Health Care Campus: Primary Outcomes: Prevention of myelotoxicity-every week during chemotherapy.
Expected Total Enrollment:  60

Study start: November 2005

Eligibility

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Female Criteria

Inclusion Criteria:

• breast cancer patient treated with adjuvant chemotherapy
• PS = 2 or less

Exclusion Criteria:

• none

Location and Contact Information

Please refer to this study by ClinicalTrials.gov identifier  NCT00243165

Georgeta Fried, MD      972-4-8543018    [email protected]

Study chairs or principal investigators
Georgeta Fried, MD,  Principal Investigator,  Rambam Health Care Campus   

More Information
Study ID Numbers:  LifemelCTIL
Last Updated:  December 8, 2005
Record first received:  October 20, 2005
ClinicalTrials.gov Identifier:  NCT00243165
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration
ClinicalTrials.gov processed this record on 2006-01-10

Source: ClinicalTrials.gov